ArticlePloS one2012
Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- Design and immunogenicity evaluation of pan-recombinant vaccines based on the consensus sequence of severe acute respiratory syndrome coronavirus-2 spike protein.Scientific reports · 2026Article
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses.Nature communications · 2025Article
- Allosteric Control and Glycan Shielding Adaptations in the SARS-CoV-2 Spike from Early to Peak Virulence.bioRxiv : the preprint server for biology · 2025Article
- Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.iScience · 2024Article
- Article
- Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice.Vaccines · 2024Article
- Article
- Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.Signal transduction and targeted therapy · 2023Review
- SARS-CoV-2 spike S2-specific neutralizing antibodies.Emerging microbes & infections · 2023Review
- Mapping immunological and host receptor binding determinants of SARS-CoV spike protein utilizing the Qubevirus platform.The Journal of biological chemistry · 2023Article
- Circularized Nanodiscs for Multivalent Mosaic Display of SARS-CoV-2 Spike Protein Antigens.Vaccines · 2023Article
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
- Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.Journal of medicinal chemistry · 2023Review
- Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.Vaccines · 2023Review
- Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory.Biomedicines · 2023Review
- SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies.Nature reviews. Microbiology · 2023Review
- Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy.Clinical reviews in allergy & immunology · 2023Review
- Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress.International journal of molecular sciences · 2023Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.